63 related articles for article (PubMed ID: 23996617)
21. Clinical Implications and Future Perspectives of Circulating Tumor Cells and Biomarkers in Clinical Outcomes of Colorectal Cancer.
Huang MY; Tsai HL; Huang JJ; Wang JY
Transl Oncol; 2016 Aug; 9(4):340-7. PubMed ID: 27567958
[TBL] [Abstract][Full Text] [Related]
22. Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options.
Rodrigues D; Longatto-Filho A; Martins SF
Biomed Res Int; 2016; 2016():6896024. PubMed ID: 27563673
[TBL] [Abstract][Full Text] [Related]
23. Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy.
Li MX; Bi XY; Zhao H; Huang Z; Han Y; Zhao DB; Zhao JJ; Cai JQ
Chin Med J (Engl); 2016 Mar; 129(5):586-93. PubMed ID: 26904994
[TBL] [Abstract][Full Text] [Related]
24. ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting.
Kim CY; Seo SH; An MS; Kim KH; Bae KB; Hwang JW; Kim JH; Kim BM; Kang MS; Oh MK; Hong KH
Ann Coloproctol; 2015 Jun; 31(3):92-7. PubMed ID: 26161376
[TBL] [Abstract][Full Text] [Related]
25. Nucleotide Excision Repair Gene ERCC2 and ERCC5 Variants Increase Risk of Uterine Cervical Cancer.
Joo J; Yoon KA; Hayashi T; Kong SY; Shin HJ; Park B; Kim YM; Hwang SH; Kim J; Shin A; Kim JY
Cancer Res Treat; 2016 Apr; 48(2):708-14. PubMed ID: 26130668
[TBL] [Abstract][Full Text] [Related]
26. A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites.
Zhang Y; Ma J; Zhang S; Deng G; Wu X; He J; Pei H; Shen H; Zeng S
Int J Colorectal Dis; 2015 Sep; 30(9):1173-83. PubMed ID: 26054387
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of excision repair cross-complementation group 1 expression in gastric cancer: A meta-analysis.
Song P; Yin Q; Lu M; Fu BO; Wang B; Zhao Q
Exp Ther Med; 2015 Apr; 9(4):1393-1400. PubMed ID: 25780441
[TBL] [Abstract][Full Text] [Related]
28. Colorectal cancer in Chinese patients: current and emerging treatment options.
Li L; Ma BB
Onco Targets Ther; 2014; 7():1817-28. PubMed ID: 25336973
[TBL] [Abstract][Full Text] [Related]
29. FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.
Mohelnikova-Duchonova B; Melichar B; Soucek P
World J Gastroenterol; 2014 Aug; 20(30):10316-30. PubMed ID: 25132748
[TBL] [Abstract][Full Text] [Related]
30. ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy.
Xian-Jun F; Xiu-Guang Q; Li Z; Hui F; Wan-Ling W; Dong L; Ping-Fa L
Pak J Med Sci; 2014 May; 30(3):488-92. PubMed ID: 24948964
[TBL] [Abstract][Full Text] [Related]
31. Predictive Value of ERCC1, ERCC2, and XRCC Expression for Patients with Locally Advanced or Metastatic Gastric Cancer Treated with Neoadjuvant mFOLFOX-4 Chemotherapy.
Yeh YS; Chen YT; Tsai HL; Huang CW; Ma CJ; Su WC; Huang CM; Huang MY; Hu HM; Lu CY; Wang JY
Pathol Oncol Res; 2020 Apr; 26(2):1105-1116. PubMed ID: 31077069
[TBL] [Abstract][Full Text] [Related]
32. [Predictive marker for the efficacy of FOLFOX treatment in colon cancer (TS, ERCC1 etc)].
Kumamoto K; Ishibashi K; Ishida H
Nihon Rinsho; 2011 Apr; 69 Suppl 3():494-9. PubMed ID: 22214010
[No Abstract] [Full Text] [Related]
33. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.
Yin M; Yan J; Martinez-Balibrea E; Graziano F; Lenz HJ; Kim HJ; Robert J; Im SA; Wang WS; Etienne-Grimaldi MC; Wei Q
Clin Cancer Res; 2011 Mar; 17(6):1632-40. PubMed ID: 21278243
[TBL] [Abstract][Full Text] [Related]
34. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
[TBL] [Abstract][Full Text] [Related]
35. ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt.
Kassem AB; Salem SE; Abdelrahim ME; Said AS; Salahuddin A; Hussein MM; Bahnassy AA
Exp Mol Pathol; 2017 Feb; 102(1):78-85. PubMed ID: 28088319
[TBL] [Abstract][Full Text] [Related]
36. Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy.
Huang MY; Huang JJ; Huang CM; Lin CH; Tsai HL; Huang CW; Chai CY; Lin CY; Wang JY
World J Surg; 2017 Nov; 41(11):2884-2897. PubMed ID: 28608017
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
